sb 216763 has been researched along with Deafness, Transitory in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bae, GS; Chong, MS; Hwang, SY; Jung, WS; Kim, DY; Kim, EK; Kim, HJ; Kim, MS; Kwon, KB; Park, CS; Park, HJ; Park, RK; Park, SJ; Seo, SW; Song, HJ; Song, MY | 1 |
1 other study(ies) available for sb 216763 and Deafness, Transitory
Article | Year |
---|---|
Selective GSK-3beta inhibitors attenuate the cisplatin-induced cytotoxicity of auditory cells.
Topics: Acoustic Stimulation; Animals; Antineoplastic Agents; Apoptosis; Caspases; Cell Line; Cisplatin; Disease Models, Animal; Dose-Response Relationship, Drug; Enzyme Activation; Evoked Potentials, Auditory, Brain Stem; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Hair Cells, Auditory; Hearing Loss; Indoles; Injections, Intraperitoneal; Interleukin-1beta; Interleukin-6; Lithium Chloride; Maleimides; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Organ Culture Techniques; Organ of Corti; Phosphorylation; Protein Kinase Inhibitors; Rats; Rats, Sprague-Dawley; Time Factors; Tumor Necrosis Factor-alpha | 2009 |